The headline trial: ESSENCE + FLOW (dual-stacked evidence)
ESSENCE (Sanyal NEJM 2025) for MASH resolution; FLOW (Perkovic NEJM 2024) for kidney composite in T2D + CKD
ESSENCE 2025; FLOW 2024
Semaglutide has FDA-labeled efficacy in both MASH resolution (ESSENCE: 62.9 percent versus 34.3 percent) and kidney composite reduction in T2D + CKD (FLOW: HR 0.76). Patients with all three conditions get cumulative organ-protective benefit from a single agent.
Trial enrollment criteria
- MASH with fibrosis stage F2 or F3 (biopsy-confirmed or non-invasive markers)
- T2D documented with HbA1c 6.5 to 10 percent
- CKD stage 3 or 4 (eGFR 25 to 75) with albuminuria
- On maximum tolerated ACE inhibitor or ARB
Does this trial apply to you?
MASH + T2D + CKD is a tightly-clustered triad that affects roughly 1 in 8 US adults with T2D. The PA case is straightforward at most commercial plans: file under MASH or T2D indication with the other conditions as supporting context. Hepatology, nephrology and endocrinology coordination strengthens the submission.
What to ask your prescriber
- Whether MASH fibrosis stage is biopsy-confirmed or non-invasive marker-based
- Most recent FibroScan, ALT/AST/GGT, eGFR, UACR, A1c
- Whether the prescribing pathway should be through hepatology, endocrinology or PCP
- Whether you need a baseline liver biopsy before initiation if not already done
Editorial notes
- Decompensated cirrhosis (Child-Pugh C) is an absolute contraindication; verify hepatic function before initiation.
- Acute kidney injury risk is amplified in MASH + CKD if dehydration occurs during GI side effects; have a pause-and-rehydrate protocol.
- Coordinate hepatology follow-up at 6 months on the first cycle to confirm ALT/AST trajectory.
Clinical trials for MASH with type 2 diabetes and chronic kidney disease
Or browse the full GLP-1 clinical trials directory, filterable by condition, state and phase.
Take it to your prescriber: PA letter templates
Editable prior-authorization letter templates that cite the registration trial above. Pick the plan your prescriber will submit to, copy the template, fill in the patient-specific findings and have your clinician sign and submit.
Not seeing your plan? The full PA letter librarycovers 20 plans × 10 indications = 200 templates. The appeal letter library handles denials.
Drug profiles
Other GLP-1 conditions
Editorial provenance
Editorial review by John, Editor on 2026-05-23, against ESSENCE + FLOW (dual-stacked evidence) (ESSENCE 2025; FLOW 2024). We do not yet have a credentialed medical reviewer on staff (actively recruiting). This page summarises public registration-trial data and FDA labeling. It is not clinician-authored medical advice.
Disclaimer
Educational summary of published registration trial data. Not medical advice. Not a substitute for evaluation by a treating clinician. Trial-level results do not guarantee individual outcomes. Discuss eligibility, contraindications, dose adjustments and drug interactions with your prescriber. We do not have a credentialed medical reviewer on staff yet (actively recruiting); the content below is editor-written from public registration-trial publications and FDA labeling, not clinician-authored medical advice.